We are live on ! Find out more
RUBY

Rubius Therapeutics, Inc
RUBY

Delisted

RUBY was delisted on the 6th of March, 2023.

Back to rankings

55 hedge funds and large institutions have $1.54B invested in Rubius Therapeutics, Inc in 2018 Q3 according to their latest regulatory filings, with 55 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
+55
Holders Change %
–
% of All Funds
1.26%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
55
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FP
Flagship Pioneering
Massachusetts
+$876M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$142M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$89.4M
4
AG
Artal Group
Luxembourg
+$66.5M
5
Capital World Investors
Capital World Investors
California
+$66.1M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1.36M +$1.29M +56,609 New
LCM
27
Laurion Capital Management
New York
$1.2M +$1.14M +50,000 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$707K +$674K +29,468 New
BCM
29
BlueCrest Capital Management
Jersey
$667K +$635K +27,795 New
Deutsche Bank
30
Deutsche Bank
Germany
$662K +$630K +27,564 New
DIM
31
DC Investments Management
Virginia
$594K +$566K +24,742 New
TA
32
Teachers Advisors
New York
$563K +$537K +23,468 New
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$441K +$420K +18,390 New
TCIM
34
TIAA CREF Investment Management
New York
$392K +$373K +16,327 New
Alyeska Investment Group
35
Alyeska Investment Group
Illinois
$382K +$364K +15,930 New
ZP
36
Zimmer Partners
New York
$360K +$343K +15,000 New
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$302K +$288K +12,600 New
MIM
38
MetLife Investment Management
New Jersey
$259K +$246K +10,781 New
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$207K +$197K +8,618 New
AIG
40
American International Group
New York
$194K +$185K +8,072 New
MLICM
41
Metropolitan Life Insurance Company (MetLife)
New York
$187K +$179K +7,809 New
Barclays
42
Barclays
United Kingdom
$109K +$104K +4,555 New
SO
43
STRS Ohio
Ohio
$84K +$80K +3,500 New
Citigroup
44
Citigroup
New York
$82K +$77.7K +3,400 New
Wells Fargo
45
Wells Fargo
California
$82K +$78.2K +3,421 New
UBS Group
46
UBS Group
Switzerland
$69K +$65.6K +2,868 New
Legal & General Group
47
Legal & General Group
United Kingdom
$44K +$42.2K +1,845 New
Bank of America
48
Bank of America
North Carolina
$38K +$36K +1,575 New
AIP
49
Ameritas Investment Partners
Nebraska
$24K +$22.9K +1,003 New
IA
50
IFP Advisors
Florida
$19K +$17.8K +779 New
1
2
3

RUBY Hedge Fund Activity: Q3 2018 in Review

55 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q3 2018, worth a combined $1.54B.

Buyers outnumbered sellers: 55 funds opened new RUBY positions and 0 closed out — a net gain of 55 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Flagship Pioneering, opening a new position worth an estimated $876M.

  • 55 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $1.54B of Rubius Therapeutics, Inc stock for Q3 2018.
  • 55 funds opened new Rubius Therapeutics, Inc positions in Q3 2018 and 0 closed out, a net change of +55 holders.
  • The largest Rubius Therapeutics, Inc buyer in Q3 2018 was Flagship Pioneering, an estimated $876M added.

Based on aggregated 13F filings for Q3 2018.